BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 31823764)

  • 41. Soluble Mesothelin-Related Peptides to Monitor Recurrence After Resection of Pleural Mesothelioma.
    Burt BM; Lee HS; Lenge De Rosen V; Hamaji M; Groth SS; Wheeler TM; Sugarbaker DJ
    Ann Thorac Surg; 2017 Nov; 104(5):1679-1687. PubMed ID: 28964420
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pleural mesothelioma and lung cancer: the role of asbestos exposure and genetic variants in selected iron metabolism and inflammation genes.
    Celsi F; Crovella S; Moura RR; Schneider M; Vita F; Finotto L; Zabucchi G; Zacchi P; Borelli V
    J Toxicol Environ Health A; 2019; 82(20):1088-1102. PubMed ID: 31755376
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mesothelin, Calretinin, and Megakaryocyte Potentiating Factor as Biomarkers of Malignant Pleural Mesothelioma.
    Jiménez-Ramírez C; Casjens S; Juárez-Pérez CA; Raiko I; Del Razo LM; Taeger D; Calderón-Aranda ES; Rihs HP; Acosta-Saavedra LC; Weber DG; Cabello-López A; Pesch B; Ochoa-Vázquez MD; Burek K; Torre-Bouscoulet L; Pérez-Padilla JR; García-Bazan EM; Brüning T; Johnen G; Aguilar-Madrid G
    Lung; 2019 Oct; 197(5):641-649. PubMed ID: 31267149
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Novel Panel of Serum Biomarkers for MPM Diagnosis.
    Bonotti A; Foddis R; Landi S; Melaiu O; De Santi C; Giusti L; Donadio E; Ciregia F; Mazzoni MR; Lucacchini A; Bovenzi M; Comar M; Pantani E; Pistelli A; Cristaudo A
    Dis Markers; 2017; 2017():3510984. PubMed ID: 28348450
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Upcoming epidemic of asbestos-related malignant pleural mesothelioma in Taiwan: A prediction of incidence in the next 30 years.
    Lin RT; Chang YY; Wang JD; Lee LJ
    J Formos Med Assoc; 2019 Jan; 118(1 Pt 3):463-470. PubMed ID: 30072200
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Detection of TGF-β in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma.
    Stockhammer P; Ploenes T; Theegarten D; Schuler M; Maier S; Aigner C; Hegedus B
    Lung Cancer; 2020 Jan; 139():124-132. PubMed ID: 31778960
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pulmonary Asbestos Fiber Burden Is Related to Patient Survival in Malignant Pleural Mesothelioma.
    Laaksonen S; Kettunen E; Sutinen E; Ilonen I; Vehmas T; Törmäkangas T; Räsänen J; Wolff H; Myllärniemi M
    J Thorac Oncol; 2022 Aug; 17(8):1032-1041. PubMed ID: 35367351
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Serum HMGB1 as a Potential Biomarker for Patients with Asbestos-Related Diseases.
    Ying S; Jiang Z; He X; Yu M; Chen R; Chen J; Ru G; Chen Y; Chen W; Zhu L; Li T; Zhang Y; Guo X; Yin X; Zhang X; Lou J
    Dis Markers; 2017; 2017():5756102. PubMed ID: 28348451
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CDKN2A copy number and p16 expression in malignant pleural mesothelioma in relation to asbestos exposure.
    Kettunen E; Savukoski S; Salmenkivi K; Böhling T; Vanhala E; Kuosma E; Anttila S; Wolff H
    BMC Cancer; 2019 May; 19(1):507. PubMed ID: 31138176
    [TBL] [Abstract][Full Text] [Related]  

  • 50. SORORIN and PLK1 as potential therapeutic targets in malignant pleural mesothelioma.
    Kato T; Lee D; Wu L; Patel P; Young AJ; Wada H; Hu HP; Ujiie H; Kaji M; Kano S; Matsuge S; Domen H; Kanno H; Hatanaka Y; Hatanaka KC; Kaga K; Matsui Y; Matsuno Y; De Perrot M; Yasufuku K
    Int J Oncol; 2016 Dec; 49(6):2411-2420. PubMed ID: 27840913
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma.
    Pass HI; Levin SM; Harbut MR; Melamed J; Chiriboga L; Donington J; Huflejt M; Carbone M; Chia D; Goodglick L; Goodman GE; Thornquist MD; Liu G; de Perrot M; Tsao MS; Goparaju C
    N Engl J Med; 2012 Oct; 367(15):1417-27. PubMed ID: 23050525
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CCL2, galectin-3, and SMRP combination improves the diagnosis of mesothelioma in pleural effusions.
    Blanquart C; Gueugnon F; Nguyen JM; Roulois D; Cellerin L; Sagan C; Perigaud C; Scherpereel A; Gregoire M
    J Thorac Oncol; 2012 May; 7(5):883-9. PubMed ID: 22729037
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Serum biomarkers in patients with mesothelioma and pleural plaques and healthy subjects exposed to naturally occurring asbestos.
    Bayram M; Dongel I; Akbaş A; Benli I; Akkoyunlu ME; Bakan ND
    Lung; 2014 Feb; 192(1):197-203. PubMed ID: 24170217
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Physician requests by patients with malignant pleural mesothelioma in Japan.
    Nagamatsu Y; Oze I; Aoe K; Hotta K; Kato K; Nakagawa J; Hara K; Kishimoto T; Fujimoto N
    BMC Cancer; 2019 Apr; 19(1):383. PubMed ID: 31023248
    [TBL] [Abstract][Full Text] [Related]  

  • 55.
    Cheng YY; Mok E; Tan S; Leygo C; McLaughlin C; George AM; Reid G
    Dis Markers; 2017; 2017():2536187. PubMed ID: 29386699
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Soluble markers for diagnosis of malignant pleural mesothelioma.
    Cristaudo A; Bonotti A; Simonini S; Bruno R; Foddis R
    Biomark Med; 2011 Apr; 5(2):261-73. PubMed ID: 21473730
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Use of Serum Mesothelin as an Indicator of Tumor Progression in Routine Clinical Practice of Malignant Pleural Mesothelioma Treatment.
    Vigani A; Pistillo MP; Fontana V; Giannoni U; Rosenberg I; Canessa PA; Berisso G; Ferro P; Franceschini MC; Tonarelli M; Roncella S
    J Thorac Oncol; 2018 Aug; 13(8):e143-e145. PubMed ID: 30049376
    [No Abstract]   [Full Text] [Related]  

  • 58. Mesothelin-family proteins and diagnosis of mesothelioma.
    Robinson BW; Creaney J; Lake R; Nowak A; Musk AW; de Klerk N; Winzell P; Hellstrom KE; Hellstrom I
    Lancet; 2003 Nov; 362(9396):1612-6. PubMed ID: 14630441
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sensitivity of urinary mesothelin in patients with malignant mesothelioma.
    Creaney J; Musk AW; Robinson BW
    J Thorac Oncol; 2010 Sep; 5(9):1461-6. PubMed ID: 20815094
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative genetic analysis of a rare synchronous collision tumor composed of malignant pleural mesothelioma and primary pulmonary adenocarcinoma.
    Naka T; Hatanaka Y; Marukawa K; Okada H; Hatanaka KC; Sakakibara-Konishi J; Oizumi S; Hida Y; Kaga K; Mitsuhashi T; Matsuno Y
    Diagn Pathol; 2016 Apr; 11():38. PubMed ID: 27091358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.